At present, immunotherapy for gastric cancer mainly includes anti-CTLA-4, anti-PD-1/PD-L1, or the combination of anti-CTLA-4 and anti-PD-1 antibodies [10]. The gene discussed is CTLA4; the disease is gastric cancer.